A REVELation in non-small-cell lung cancer treatment?

Mené sur 1 825 patients atteints d'un cancer du poumon non à petites cellules de stade IV, cet essai multicentrique de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicite du ramucirumab en complément du docétaxel pour un traitement de deuxième ligne

Résumé en anglais

REVEL, reported in The Lancet , was a positive study. Edward Garon and colleagues document an improvement in median overall survival with docetaxel and ramucirumab (10·5 months) as compared with docetaxel plus placebo (9·1 months; HR 0·86, 95% CI 0·75—0·98) as second-line therapy for advanced, previously treated non-small-cell lung cancer (NSCLC). The implications of this positive randomised phase 3 trial need to be appraised—this publication might lead to approval of ramucirumab as...